Labcorp to acquire BioReference Health assets for $722 million
Labcorp (LH) will buy select BioReference Health assets from OPKO Health (OPK) for $722M, with up to $150M more in earnouts. The deal includes 80+ patient service centers and the 4Kscore Test. Labcorp expects $250M in first-year revenue. Regulatory approval is pending. Lazard and Hogan Lovells advise Labcorp; Piper Sandler and Greenberg Traurig advise OPKO.
How this was made
The 30-second read
Why it matters
The transaction is expected to boost Labcorp's revenue diversification while providing OPKO cash to focus on its biopharma pipeline.
Market read
First‑report of a $722M acquisition that reshapes the U.S. diagnostics landscape and may move both LH and OPK stocks.
What to watch
Potential regulatory scrutiny of the 4Kscore Test market and the earnout contingent on test revenue may affect deal economics.
Background
The deal combines Labcorp's diagnostic capabilities with OPKO's BioReference testing platform, including the FDA‑approved 4Kscore prostate cancer test.
Ticker impact
Labcorp announced a $722M cash acquisition of BioReference Health assets from OPKO, adding new testing services and the 4Kscore Test.
likely upward pressure on LH as investors price in expanded service portfolio; likely downside pressure on OPKO as it divests assets.
Large cash deal expands Labcorp's revenue base; OPKO receives cash and can focus on biopharma, but loss of revenue-generating assets may concern investors.
OPKO Health agreed to sell BioReference Health assets to Labcorp for $722M cash plus up to $150M earnout.
likely modest downside as market assesses loss of testing revenue versus cash proceeds.
Cash infusion improves balance sheet, yet removal of a steady‑revenue segment may be viewed negatively until new biopharma pipeline progress is clear.
Market effects
strengthens Labcorp's position in clinical diagnostics and women's health testing, may spur consolidation in the lab services sector.
U.S. healthcare and diagnostics markets see increased M&A activity; no immediate foreign market effect.
Adds to global trend of large diagnostics firms expanding service lines through acquisitions.
Counterpoint
The acquisition could overpay for BioReference assets, leading to integration risk and margin pressure for Labcorp.
Key entities
- CompanyLabcorp
U.S. clinical laboratory services provider (ticker LH).
- CompanyOPKO Health
Biopharmaceutical company selling BioReference Health assets (ticker OPK).
